ClinicalTrials.gg
RecruitingNCT07288333Updated Jul 22, 2026

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

A Phase 2 interventional study of NBI-1117570 and Placebo in Schizophrenia, sponsored by Neurocrine Biosciences. Recruiting at 6 sites in 3 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.

Planned enrollment
9th of 16
120 · median 165
Started
2026
the only one that year
Phase 2
6 of 16
1 open now
Registered
16th of 16
by date

Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 2, and was the 16th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Schizophrenia by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • NBI-1117570
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • 18 to 55 years of age
  • Primary diagnosis of schizophrenia ≥1 year before screening.
  • Participant is experiencing an acute exacerbation or relapse of symptoms with onset less than 2 months before screening and currently requires hospitalization.
  • Participant must have had a positive response to at least 1 antipsychotic therapy (other than clozapine) for the treatment of a prior acute relapse.

Key Exclusion Criteria:

  • Considered to be at imminent risk of suicide or injury to self or others.
  • History of epilepsy, seizures, or convulsions.
  • Has orthostatic hypotension, or history of pulmonary hypertension, obstructive coronary artery disease, hypertrophic cardiomyopathy, myocardial infarction, coronary artery revascularization, heart failure, left ventricular hypertrophy, moderate or severe cardiac valvopathy, or other cardiovascular conditions or measures that would preclude participation.
  • Currently taking prohibited medications.
  • Pregnant or lactating.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    NBI-1117570: Lower-dose

    Participants will receive a lower-dose of NBI-1117570.

    Drug: NBI-1117570

  • Experimental
    NBI-1117570: Higher-dose

    Participants will receive a higher-dose of NBI-1117570.

    Drug: NBI-1117570

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to NBI-1117570.

    Drug: Placebo

Interventions

  • DrugNBI-1117570

    Oral administration

  • DrugPlacebo

    Oral administration

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 35

    Time frame: Day 35

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Event (TEAEs)

    Time frame: Day 1 up to Day 49

07

Study locations

6 of 6 sites recruiting
  • Neurocrine Clinical Site
    Kazanlak, 6100, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Pazardzhik, 4400, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Targovishte, 7700, Bulgaria
    Recruiting
  • Neurocrine Clinical Site
    Târgu Mureş, 540136, Romania
    Recruiting
  • Neurocrine Clinical Site
    London, SE5 8AZ, United Kingdom
    Recruiting
  • Neurocrine Clinical Site
    Oxford, OX3 7JX, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2027, 18 months after the start.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's planned 18 months is close to that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 17, 2025
StartActual
Feb 16, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07288333
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Feb 16, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jul 22, 2026

Study contacts

Neurocrine Medical Information Call Center
Contact
medinfo@neurocrine.com
1-877-641-3461
Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion